To our knowledge, this is the first report of OX40, PD-1 and CTLA-4 expression levels in the TIL and peripheral lymphocytes from SCCHN patients and provides rationale for combination therapy with these agents in this disease. This evidence concerns the gene TNFRSF4 and head and neck squamous cell carcinoma.